Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)

Cancer Causes and Control

Volumn 14, Issue 5, 2003, Pages 439-446

  Modugno, Francesmary ^a   Moslehi, Roxana ^b   Ness, Roberta B ^a   Nelson, Deborah Brooks ^c   Belle, Steven ^a   Kant, Jeffrey A ^d   Wheeler, James E ^c   Wonderlick, Aimee ^h   Fishman, David ^h   Karlan, Beth ^e   Risch, Harvey ^f   Cramer, Daniel W ^g   Dube, Marie Pierre ^b   Narod, Steven A ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f YALE UNIVERSITY   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NONE

Author keywords

BRCA1; Oral contraceptives; Ovarian cancer; Parity

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BIRTH RATE; BREAST FEEDING; CANCER INVASION; CANCER RISK; CHILDBIRTH; CONFIDENCE INTERVAL; COVARIANCE; DOSE TIME EFFECT RELATION; EPITHELIUM CELL; FEMALE; GENE DELETION; GENE MUTATION; GYNECOLOGIC SURGERY; HETEROZYGOTE; HUMAN; JEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NULLIPARA; ONCOGENE; ONSET AGE; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; REPRODUCTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGICAL RISK; UNITED STATES; UTERINE TUBE LIGATION;

ADULT; AGED; BREAST FEEDING; CONTRACEPTIVES, ORAL; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; JEWS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS; STERILIZATION, TUBAL; UNITED STATES;

EID: 0043234708     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024932427503     Document Type: Article

References (23)

1. Ozols RF, Rubin SC, Thomas G, Robboy S (1997) Epithelial Ovarian Cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott-Raven.
2. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) Attributable risk of breast and ovarian cancer. Cancer 77: 2318-2324.
3. Risch HA, McLaughlin JR, Cole DE, et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Amer J Hum Genet 68: 700-710.
4. Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504.
5. Struewing JP, Hartge P, Wacholder S, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med 336: 1401-1408.
6. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1184-1203.
7. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL (1990) Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43: 559-568.
8. Rosenblatt KA, Thomas DB, The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1996) Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidemiol Biomarkers Prev 5: 933-935.
9. Narod SA, Risch HA, Moslehi R, et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. New Engl J Med 339: 424-428.
10. Modan B, Hartge P, Hirsh-Yechezkel G, et al. (1926) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345: 235-240.
11. Moslehi R, Chu W, Karlan B, et al. (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66: 1259-1272.
12. Ness RB, Grisso J, Klapper J, et al. (2000) Risk of ovarian cancer in relation to estrogen dose and use characteristics of oral contraceptives. Am J Epidemiol 152: 233-241.
13. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC (1999) A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93: 34-37.
14. Hogervorst FB, Cornelis RS, Bout M, et al. (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208-212.
15. Khoury MJ, Flanders WD (1996) Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 144: 207-213.
16. Modugno F, Ness RB, Wheeler JE (2001) Reproductive Risk Factors for Epithelial Ovarian Cancer According to Histologic Type and Invasiveness. Ann Epidemiol 11(8): 568-574.
17. Kreiger N, Sloan M, Cotterchio M, Parsons P (1997) Surgical procedures associated with risk of ovarian cancer. Intl J Epidemiol 26: 710-715.
18. Green A, Purdie D, Bain C, et al. (1997) Tubal sterilization, hysterectomy and decreased risk of ovarian cancer: survey of Women's Health Study Group. Int J Cancer 71: 948-951.
19. Cornelison TL, Nartarajan N, Piver MS, Mettlin CJ (1997) Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev 21: 1-6.
20. Narod SA, Sun P, Ghadirian P, et al. (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case - control study. Lancet 357: 1467-1470.
21. Frank TS, Deffenbaugh AM, Reid JE, et al. (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20: 1480-1490.
22. Boyd J, Sonoda Y, Federici MG, et al. (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283: 2260-2265.
23. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S (2001) Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol 154: 687-693.